LINC01494: A Potential Drug Target and Biomarker (G101928537)

Target Name: LINC01494

NCBI ID: G101928537

LINC01494

Other Name(s): Long intergenic non-protein coding RNA 1494 | long intergenic non-protein coding RNA 1494

LINC01494: A Potential Drug Target and Biomarker

LINC01494 is a long intergenic non-protein coding RNA (lncRNA) that has been identified in various studies as having potential drug targets and biomarkers. This RNA is highly expressed in various tissues and has been associated with various diseases, including cancer. Therefore, it is of great interest to investigate the potential drug targets and biomarkers of LINC01494.

Drug Targets

LINC01494 has been shown to have several potential drug targets. Firstly, LINC01494 has been shown to play a role in the regulation of cell cycle progression. It has been shown to promote the G1 phase and inhibit the S phase, which are important steps in the cell cycle. Therefore, LINC01494 may be a drug target for therapies that target cell cycle regulation.

Secondly, LINC01494 has been shown to be involved in the regulation of gene expression. It has been shown to interact with various transcription factors, including NF-kappa-B and SMAD3. Therefore, LINC01494 may be a drug target for therapies that target gene expression regulation.

Thirdly, LINC01494 has been shown to be involved in the regulation of cell survival. It has been shown to be involved in the regulation of cell survival and has been shown to play a role in the development of cancer. Therefore, LINC01494 may be a drug target for therapies that target cell survival.

Biomarkers

LINC01494 has also been shown to have potential as a biomarker for various diseases, including cancer. Firstly, LINC01494 has been shown to be downregulated in various cancer tissues. Therefore, it may be a potential biomarker for cancer.

Secondly, LINC01494 has been shown to be involved in the regulation of cellular processes that are important for cancer progression. For example, LINC01494 has been shown to be involved in the regulation of cell migration and invasion, which are important steps in cancer progression. Therefore, LINC01494 may be a potential biomarker for cancer.

Thirdly, LINC01494 has been shown to be involved in the regulation of the immune response. It has been shown to play a role in the regulation of T cell development and has been shown to be involved in the regulation of immune surveillance. Therefore, LINC01494 may be a potential biomarker for cancer.

Conclusion

In conclusion, LINC01494 is a long intergenic non-protein coding RNA that has potential as a drug target and biomarker. Its potential drug targets include cell cycle regulation, gene expression regulation, and cell survival. Its potential as a biomarker includes its involvement in cancer and its role in the regulation of cellular processes that are important for cancer progression. Further research is needed to fully understand the potential of LINC01494 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1494

The "LINC01494 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01494 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets